Across TCGA pan-cancer cohorts, CEP70 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CEP70 data layer compared with 23 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CEP70 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CEP70 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.
PDAC and LSCC are the cancer types where CEP70 mass-spec protein most reproducibly stratifies survival.